Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan.

Anthracycline- and taxane-based chemotherapy regimens are established treatments for human epidermal growth factor receptor (HER)2-negative early-stage breast cancer with high risk of recurrence. This study examined the prevalence of these chemotherapy regimens as perioperative therapy, the patterns of retreatment, and factors influencing prescription choices in Japan. This observational cohort study focused on high-risk early-stage breast cancer patients not undergoing anti-HER2 therapy, utilizing data from a hospital-based claims database in Japan spanning from April 2008 to September 2021. Of 42,636 high-risk patients who underwent breast cancer surgery, 32,133 (75.4%) were categorized as having luminal-type (received endocrine therapy) and 10,503 (24.6%) as having triple-negative cancer (not receiving any endocrine therapies). Most patients (98.7%) with luminal-type breast cancer received perioperative therapy, and 40.3% of those received anthracycline/taxane. In the triple-negative group, 57.0% of all patients received perioperative therapy and of those, 93.4% received anthracycline/taxane. Being over 40 years old, having an early stage (clinical stage ≤ II), and receiving treatment in non-specialized facilities were associated with less use of anthracycline/taxane in the luminal-type group. For the triple-negative group, associated factors with less use of anthracycline/taxane included being over 60 years old, treatment in small hospital (capacity < 200 beds), and treatment in non-specialized facilities. Approximately half the patients in both the luminal-type and triple-negative groups were prescribed anthracycline and/or taxane for perioperative chemotherapy. The choice was associated with patient age, cancer stage, and the scale and specialization of the treatment facilities. This study sheds light on the current state of breast cancer treatment practices in Japan.

Shimomura A ，Sagara Y ，Koto R ，Fujiwara M ，Kanemura Y ，Kitagawa H ，Saji S ... -  《-》

Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.

Hojo T ，Masuda N ，Iwamoto T ，Niikura N ，Anan K ，Aogi K ，Ohnishi T ，Yamauchi C ，Yoshida M ，Kinoshita T ，Masuoka H ，Sagara Y ，Sakatani T ，Kojima Y ，Tsuda H ，Kumamaru H ，Miyata H ，Nakamura S ... -  《-》

Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.

Lee HJ ，Park IA ，Song IH ，Kim SB ，Jung KH ，Ahn JH ，Ahn SH ，Kim HH ，Gong G ... -  《PLoS One》

Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.

Dörfel S ，Steffens CC ，Meyer D ，Tesch H ，Kruggel L ，Frank M ，Jänicke M ，Marschner N ，TMK-Group (Tumour Registry Breast Cancer) ... -  《-》

Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.

Wang S ，Shi Y ，Yuan Z ，Wang X ，Liu D ，Peng R ，Teng X ，Qin T ，Peng J ，Lin G ，Jiang X ... -  《-》